Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms. The company serves generic drug companies; and companies that discover and commercialize small molecule human therapeutics. The company sells its products directly, as well as through independent agents. Cambrex Corporation was founded in 1981 and is headquartered in East Rutherford, New Jersey.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Phone201-804-3000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$532.09 million
Profitability
Miscellaneous
Employees1,732
Next Earnings Date8/1/2019 (Estimated)
OptionableOptionable
Cambrex (NYSE:CBM) Frequently Asked Questions
What is Cambrex's stock symbol?
Cambrex trades on the New York Stock Exchange (NYSE) under the ticker symbol "CBM."
How were Cambrex's earnings last quarter?
Cambrex Co. (NYSE:CBM) announced its quarterly earnings data on Thursday, May, 2nd. The biotechnology company reported $0.31 EPS for the quarter, topping analysts' consensus estimates of $0.21 by $0.10. The biotechnology company earned $159.46 million during the quarter, compared to analysts' expectations of $159.71 million. Cambrex had a return on equity of 12.25% and a net margin of 14.35%. The firm's quarterly revenue was up 13.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.72 earnings per share. View Cambrex's Earnings History.
When is Cambrex's next earnings date?
What price target have analysts set for CBM?
4 equities research analysts have issued 1-year target prices for Cambrex's shares. Their predictions range from $43.00 to $55.00. On average, they anticipate Cambrex's stock price to reach $46.75 in the next twelve months. This suggests a possible upside of 9.0% from the stock's current price. View Analyst Price Targets for Cambrex.
What is the consensus analysts' recommendation for Cambrex?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cambrex in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cambrex.
Has Cambrex been receiving favorable news coverage?
Headlines about CBM stock have trended positive this week, InfoTrie reports. The research group ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Cambrex earned a media sentiment score of 2.3 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 9.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the near term.
Who are some of Cambrex's key competitors?
Some companies that are related to Cambrex include Amarin (AMRN), Nektar Therapeutics (NKTR), GW Pharmaceuticals PLC- (GWPH), Ascendis Pharma A/S (ASND), Array Biopharma (ARRY), American Brivision (Holding) (ABVC), TESARO (TSRO), Blueprint Medicines (BPMC), United Therapeutics (UTHR), Taro Pharmaceutical Industries (TARO), Alkermes (ALKS), ACADIA Pharmaceuticals (ACAD), HUTCHISON CHINA/S (HCM), Ultragenyx Pharmaceutical (RARE) and Global Blood Therapeutics (GBT).
What other stocks do shareholders of Cambrex own?
Who are Cambrex's key executives?
Cambrex's management team includes the folowing people:
- Mr. Steven M. Klosk, Pres, CEO & Director (Age 62)
- Mr. Gregory P. Sargen, Exec. VP of Corp. Devel. & Strategy and CFO (Age 53)
- Mr. Shawn P. Cavanagh, Exec. VP & COO (Age 53)
- Ms. Samantha M. Hanley, VP, Gen. Counsel & Corp. Sec. (Age 41)
- Mr. James G. Farrell, VP & Corp. Controller (Age 52)
Who are Cambrex's major shareholders?
Cambrex's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (14.47%), William Blair Investment Management LLC (7.90%), Dimensional Fund Advisors LP (4.18%), Lazard Asset Management LLC (2.75%), Goldman Sachs Group Inc. (2.37%) and American Capital Management Inc. (2.27%). Company insiders that own Cambrex stock include Gregory Sargen, Ilan Kaufthal, Leon J Hendrix Jr, Samantha Hanley, Shawn Cavanagh, Steven M Klosk and Tom George Vadaketh. View Institutional Ownership Trends for Cambrex.
Which institutional investors are selling Cambrex stock?
CBM stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Acadian Asset Management LLC, SEI Investments Co, New Amsterdam Partners LLC NY, LSV Asset Management, Wells Fargo & Company MN, JPMorgan Chase & Co. and First Trust Advisors LP. Company insiders that have sold Cambrex company stock in the last year include Gregory Sargen, Ilan Kaufthal, Samantha Hanley, Shawn Cavanagh, Steven M Klosk and Tom George Vadaketh. View Insider Buying and Selling for Cambrex.
Which institutional investors are buying Cambrex stock?
CBM stock was purchased by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, Granite Investment Partners LLC, Lazard Asset Management LLC, Royce & Associates LP, American Capital Management Inc., Morgan Stanley, William Blair Investment Management LLC and Tributary Capital Management LLC. View Insider Buying and Selling for Cambrex.
How do I buy shares of Cambrex?
Shares of CBM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cambrex's stock price today?
One share of CBM stock can currently be purchased for approximately $42.89.
How big of a company is Cambrex?
Cambrex has a market capitalization of $1.44 billion and generates $532.09 million in revenue each year. The biotechnology company earns $92.41 million in net income (profit) each year or $2.77 on an earnings per share basis. Cambrex employs 1,732 workers across the globe.
What is Cambrex's official website?
How can I contact Cambrex?
Cambrex's mailing address is ONE MEADOWLANDS PLZ, EAST RUTHERFORD NJ, 07073. The biotechnology company can be reached via phone at 201-804-3000 or via email at [email protected]
MarketBeat Community Rating for Cambrex (NYSE CBM)
MarketBeat's community ratings are surveys of what our community members think about Cambrex and other stocks. Vote "Outperform" if you believe CBM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBM will underperform the S&P 500 over the long term. You may vote once every thirty days.
